COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Identification and Validation of Functional Biomarkers for Keratoconus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01746823
Recruitment Status : Unknown
Verified December 2012 by Dr Rohit Shetty, Narayana Nethralaya.
Recruitment status was:  Recruiting
First Posted : December 11, 2012
Last Update Posted : March 6, 2014
Singapore Eye Research Institute
Information provided by (Responsible Party):
Dr Rohit Shetty, Narayana Nethralaya

Brief Summary:
There is currently no medication for containing KC, nor any adequate biomarkers to predict the disease. Furthermore, there is considerable confusion in the field regarding the pathophysiology of the disease and involvement of inflammation. To that end, this study is designed to address some of these questions by determining the proteomic profiles of KC patients with different clinical grades. This relatively large cohort study is expected to yield significant information regarding the molecules that are deregulated during progression of KC and may provide a framework to assign diagnostic biomarkers and therapeutic intervention points.

Condition or disease Intervention/treatment
Keratoconus Drug: Cyclosporins

Detailed Description:

The screening of keratoconus involves keratoconus related clinical signs like retinoscopy scissors reflex, Munson sign, stromal thinning, Vogt's striae, and Fleischer's ring, but corneal topography is the most useful method in the diagnosis of keratoconus, especially in the absence of clinical signs.

Several devices are currently available for detecting early keratoconus by measuring anterior and posterior corneal topography and elevation(Mihaltz et al. 2009; Ishii et al. 2012). Corneal topographic and tomographic techniques which generate color-coded maps and topographic indices, are the most sensitive devices for confirming the diagnosis of keratoconus(Rabinowitz 1998; Rao et al. 2002) were used for diagnosis in this study. In addition, videokeratography has been shown to identify Forme fruste keratoconus (FFKC) in the absence of clinical signs of keratoconus. Videokeratographic indices such as the Klyce/Maeda criteria, the Rabinowitz criteria, and others have been developed to quantitatively analyze videokeratography and screen for keratoconus(Rao et al. 2002). These indices have been shown to identify keratoconus with a high degree of sensitivity and specificity. The Orbscan II is a three-dimensional slit-scan topography system for analysis of the corneal surfaces and anterior chamber and has been used on all patients in the study. It uses calibrated video and a scanning slit beam to measure x, y, and z locations of several thousand points. These points are used to construct topographic maps(Rao et al. 2002). The Pentacam (Oculus Inc) is a corneal tomographer technology which generates data on topograophy and elevation of anterior and posterior using a rotating Scheimpflug camera which has also been used on all subjects enrolled in this study. Various diagnostic parameters are available for keratoconus diagnosis depending on what mode of topography is being used. Maeda and Klyce designed a system to detect keratoconus. The system, which is based on linear discriminant analysis and a binary decision tree, identifies the map as representing keratoconus or nonkeratoconus and, based on a value from the discriminant analysis (the KPI), assigns the map an index expressed as a percentage that suggests the severity of keratoconus. At this time, however, Keratoconus Severity Index (KSI) and the Amsler-Krumeich classification are the most popular methods for grading keratoconus severity(Mihaltz et al. 2009; Ishii et al. 2012). KSI is based on indices estimated by a curvature map using Placido disk-based corneal topography, and Amsler-Krumeich classification defines the stage of keratoconus using biomicroscopy, mean central keratometry reading, spherical and cylindrical refraction change, and corneal thickness(Mihaltz et al. 2009; Ishii et al. 2012). This is the index that has been used for the final gradation of keratoconus stages of all subjects in this study.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 200 participants
Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration: 6 Months
Official Title: Identification of Disease Progression Specific Biomarkers and Their Pharmacologic Modulation for Keratoconus.
Study Start Date : April 2013
Estimated Primary Completion Date : December 2015
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Controls, Keratoconus
Sub group of Keratoconus to be treated with anti-inflammatory agents ie Cyclosporine-A
Drug: Cyclosporins
Other Name: Restasis

Primary Outcome Measures :
  1. Keratoconus grade specific biomarker identification [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Onlabel use of anti-allergic topical treatment for inhibition of specific biomarkers to modify keratoconus disease progression [ Time Frame: 2 years ]

Biospecimen Retention:   Samples Without DNA
Tear samples and discarded epithelium from Keratoplasty surgeries.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients detected with corneal thinning by keratometry at a tertiary level hospital

Inclusion Criteria:

  • Evidence of corneal thinning by any type of keratometry

Exclusion Criteria:

  • Corneal inflammation without evidence of ectasia
  • Retinal disorder subjects excluded

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01746823

Layout table for location information
Narayana Nethralaya Recruiting
Bangalore, Karnataka, India, 560010
Contact: Rohit Shetty, DNB, FRCS    91-9611102568   
Principal Investigator: Rohit Shetty, MBBS, DNB, FRCS         
Sponsors and Collaborators
Narayana Nethralaya
Singapore Eye Research Institute
Layout table for investigator information
Principal Investigator: Rohit Shetty, MBBS,DNB, FRCS Narayana Nethralaya
Additional Information:

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr Rohit Shetty, Consultant, Cornea and Refractive Services, Narayana Nethralaya Identifier: NCT01746823    
Other Study ID Numbers: NNKC-2011
First Posted: December 11, 2012    Key Record Dates
Last Update Posted: March 6, 2014
Last Verified: December 2012
Keywords provided by Dr Rohit Shetty, Narayana Nethralaya:
Additional relevant MeSH terms:
Layout table for MeSH terms
Corneal Diseases
Eye Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors